In the absence of a consensus on the minimum expected benefit to validate MRI or mastectomy, the authors suggest based on their data that these options should be offered to all BRCA1/BRCA2 carriers with Stage I/II ovarian cancer, but only offered to those with Stage III/IV ovarian cancer diagnosed before age 50 or at least 10 years post ovarian cancer diagnosis without recurrence. The gene discussed is BRCA2; the disease is ovarian cancer.